6533b834fe1ef96bd129e0fb

RESEARCH PRODUCT

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile

Diletta ArcidiaconoLaura D'erasmoSara De MartinNicola FerriFabio FimianiAlice ZaramellaAngelo B. CefalùMaria Giovanna LupoPaolo CalabròAlberto ZambonMaurizio AvernaMarcello Arca

subject

Drugmedicine.medical_specialtymedia_common.quotation_subjectFamilial hypercholesterolemiaPCSK9chemistry.chemical_compoundInternal medicineLomitapide Lipoprotein (a) PCSK9 Familial HypercholesterolemiaLipoprotein (a)Internal MedicinemedicineDiseases of the circulatory (Cardiovascular) systemFamilial Hypercholesterolemiaskin and connective tissue diseasesmedia_commonLdl cholesterolmedicine.diagnostic_testbusiness.industryPCSK9nutritional and metabolic diseasesPlasma levelsmedicine.diseaseLomitapideLomitapidelp(a)EndocrinologychemistryRC666-701pcsk9.lipids (amino acids peptides and proteins)sense organsCardiology and Cardiovascular MedicineLipid profilebusiness

description

Abstract Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.

yearjournalcountryeditionlanguage
2021-09-01
10.1016/j.athplu.2021.05.001http://hdl.handle.net/11577/3395328